IMCR
Immunocore Holdings Ltd
NASDAQ: IMCR · HEALTHCARE · BIOTECHNOLOGY
$27.92
-3.02% today
Updated 2026-04-29
Market cap
$1.42B
P/E ratio
—
P/S ratio
3.55x
EPS (TTM)
$-0.71
Dividend yield
—
52W range
$27 – $41
Volume
0.4M
Immunocore Holdings Ltd (IMCR) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-8.88%
Operating margin
0.04%
ROE
-9.58%
ROA
-1.54%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $3.30M | $-5.96M | 100.00% | -234.32% | -180.63% |
| 2014 | $10.29M | $-9.02M | 100.00% | -114.61% | -87.70% |
| 2015 | $16.93M | $19.88M | 100.00% | -119.18% | 117.43% |
| 2016 | $20.21M | $-28.40M | 100.00% | -197.27% | -140.50% |
| 2017 | $19.17M | $-65.76M | 100.00% | -473.67% | -343.13% |
| 2018 | $23.65M | $-71.63M | 100.00% | -395.09% | -302.82% |
| 2019 | $25.67M | $-103.93M | -289.54% | -460.95% | -404.89% |
| 2020 | $30.11M | $-74.09M | -148.42% | -286.22% | -246.04% |
| 2021 | $27.04M | $-133.45M | 100.00% | -478.53% | -493.45% |
| 2022 | $144.23M | $-43.46M | 96.33% | -29.66% | -30.13% |
| 2023 | $197.39M | $-43.75M | 99.58% | -23.91% | -22.17% |
| 2024 | $247.98M | $-40.81M | 97.76% | -22.70% | -16.45% |
| 2025 | $297.57M | $-26.42M | 97.91% | -11.34% | -8.88% |